title: Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm.
abstract: For protection from HIV-1 infection, a vaccine should elicit both humoral and cell-mediated immune responses. A novel vaccine regimen and adjuvant that induce high levels of HIV-1 Env-specific T cell and antibody (Ab) responses was developed in this study. The prime-boost regimen that used combinations of replication-competent vaccinia LC16m8Δ (m8Δ) and Sendai virus (SeV) vectors expressing HIV-1 Env efficiently produced both Env-specific CD8(+) T cells and anti-Env antibodies, including neutralizing antibodies (nAbs). These results sharply contrast with vaccine regimens that prime with an Env expressing plasmid and boost with the m8Δ or SeV vector that mainly elicited cellular immunities. Moreover, co-priming with combinations of m8Δs expressing Env or a membrane-bound human CD40 ligand mutant (CD40Lm) enhanced Env-specific CD8(+) T cell production, but not anti-Env antibody production. In contrast, priming with an m8Δ that coexpresses CD40Lm and Env elicited more anti-Env Abs with higher avidity, but did not promote T cell responses. These results suggest that the m8Δ prime/SeV boost regimen in conjunction with CD40Lm expression could be used as an immunization platform for driving both potent cellular and humoral immunities against pathogens such as HIV-1.
authors.affiliation: Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo, Japan.
authors.forename: Xianfeng
authors.initials: X
authors.lastname: Zhang
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Sobue
authors.forename: Mao
authors.initials: M
authors.lastname: Isshiki
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Makino
authors.forename: Makoto
authors.initials: M
authors.lastname: Inoue
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kato
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Shioda
authors.forename: Takashi
authors.initials: T
authors.lastname: Ohashi
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Sato
authors.forename: Jun
authors.initials: J
authors.lastname: Komano
authors.forename: Hideji
authors.initials: H
authors.lastname: Hanabusa
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Shida
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D023201:CD40 Ligand / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D017931:DNA Primers / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D057809:HEK293 Cells; D015497:HIV-1; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D056724:Immunity, Humoral / Q000276:immunology*; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D016133:Polymerase Chain Reaction; D029082:Sendai virus; D014616:Vaccinia virus; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D057134:Antibodies, Neutralizing; D017931:DNA Primers; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D054299:env Gene Products, Human Immunodeficiency Virus; D023201:CD40 Ligand